Gilead Sciences (NASDAQ:GILD) Sets New 1-Year High – What’s Next?

Gilead Sciences, Inc. (NASDAQ:GILD)’s stock price hit a new 52-week high on Monday . The company traded as high as $118.81 and last traded at $118.87, with a volume of 456889 shares trading hands. The stock had previously closed at $117.41.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on GILD shares. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Wednesday, February 12th. UBS Group increased their target price on shares of Gilead Sciences from $70.00 to $96.00 and gave the stock a “neutral” rating in a report on Thursday, November 21st. Morgan Stanley lifted their price target on shares of Gilead Sciences from $113.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 12th. Oppenheimer boosted their price target on shares of Gilead Sciences from $115.00 to $132.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 4th. Finally, Royal Bank of Canada raised their price objective on Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a report on Wednesday, February 12th. Eleven investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and four have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $104.24.

Gilead Sciences Trading Up 1.5 %

The firm has a market capitalization of $148.36 billion, a P/E ratio of 320.79, a P/E/G ratio of 0.71 and a beta of 0.21. The company has a current ratio of 1.50, a quick ratio of 1.20 and a debt-to-equity ratio of 1.24. The firm has a 50-day moving average of $99.61 and a two-hundred day moving average of $91.62.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be given a $0.79 dividend. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 annualized dividend and a yield of 2.65%. Gilead Sciences’s dividend payout ratio (DPR) is currently 854.05%.

Insider Buying and Selling

In other Gilead Sciences news, CFO Andrew D. Dickinson sold 2,500 shares of the company’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $104.09, for a total transaction of $260,225.00. Following the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. This represents a 1.46 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Insiders have sold a total of 293,356 shares of company stock worth $29,166,240 in the last ninety days. Company insiders own 0.16% of the company’s stock.

Institutional Investors Weigh In On Gilead Sciences

Several institutional investors and hedge funds have recently made changes to their positions in the business. Redwood Financial Network Corp increased its stake in shares of Gilead Sciences by 4.0% in the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock valued at $234,000 after acquiring an additional 98 shares in the last quarter. Nicolet Advisory Services LLC raised its holdings in shares of Gilead Sciences by 2.9% during the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the period. Avior Wealth Management LLC grew its stake in shares of Gilead Sciences by 1.2% in the 3rd quarter. Avior Wealth Management LLC now owns 9,422 shares of the biopharmaceutical company’s stock valued at $782,000 after buying an additional 108 shares during the period. Southland Equity Partners LLC boosted its holdings in Gilead Sciences by 3.6% in the fourth quarter. Southland Equity Partners LLC now owns 3,128 shares of the biopharmaceutical company’s stock worth $289,000 after acquiring an additional 110 shares in the last quarter. Finally, Concord Asset Management LLC VA increased its holdings in shares of Gilead Sciences by 3.8% during the third quarter. Concord Asset Management LLC VA now owns 3,056 shares of the biopharmaceutical company’s stock valued at $256,000 after acquiring an additional 111 shares in the last quarter. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.